278 related articles for article (PubMed ID: 29945887)
1. DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson's disease.
Krishnan N; Felice C; Rivera K; Pappin DJ; Tonks NK
Genes Dev; 2018 Jul; 32(13-14):944-952. PubMed ID: 29945887
[TBL] [Abstract][Full Text] [Related]
2. Activation of HIF-1 signaling ameliorates liver steatosis in zebrafish atp7b deficiency (Wilson's disease) models.
Mi X; Li Z; Yan J; Li Y; Zheng J; Zhuang Z; Yang W; Gong L; Shi J
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165842. PubMed ID: 32446740
[TBL] [Abstract][Full Text] [Related]
3. Toxic milk mice models of Wilson's disease.
Hadrian K; Przybyłkowski A
Mol Biol Rep; 2021 Feb; 48(2):1903-1914. PubMed ID: 33590415
[TBL] [Abstract][Full Text] [Related]
4. The link between copper and Wilson's disease.
Purchase R
Sci Prog; 2013; 96(Pt 3):213-23. PubMed ID: 24244969
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease.
Wooton-Kee CR
Pharmacol Ther; 2023 Nov; 251():108529. PubMed ID: 37741465
[TBL] [Abstract][Full Text] [Related]
6. [The onset of psychiatric disorders and Wilson's disease].
Benhamla T; Tirouche YD; Abaoub-Germain A; Theodore F
Encephale; 2007 Dec; 33(6):924-32. PubMed ID: 18789784
[TBL] [Abstract][Full Text] [Related]
7. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
8. The treatment of Wilson's disease, a rare genetic disorder of copper metabolism.
Purchase R
Sci Prog; 2013; 96(Pt 1):19-32. PubMed ID: 23738435
[TBL] [Abstract][Full Text] [Related]
9. In
Sharma Y; Liu J; Kristian KE; Follenzi A; Gupta S
Gene Expr; 2018 Dec; 19(1):15-24. PubMed ID: 30029699
[TBL] [Abstract][Full Text] [Related]
10. Laser ablation inductively coupled plasma mass spectrometry imaging of metals in experimental and clinical Wilson's disease.
Boaru SG; Merle U; Uerlings R; Zimmermann A; Flechtenmacher C; Willheim C; Eder E; Ferenci P; Stremmel W; Weiskirchen R
J Cell Mol Med; 2015 Apr; 19(4):806-14. PubMed ID: 25704483
[TBL] [Abstract][Full Text] [Related]
11. Cell therapy to remove excess copper in Wilson's disease.
Gupta S
Ann N Y Acad Sci; 2014 May; 1315(1):70-80. PubMed ID: 24820353
[TBL] [Abstract][Full Text] [Related]
12. Wilson's disease: update on pathogenesis, biomarkers and treatments.
Shribman S; Poujois A; Bandmann O; Czlonkowska A; Warner TT
J Neurol Neurosurg Psychiatry; 2021 Oct; 92(10):1053-1061. PubMed ID: 34341141
[TBL] [Abstract][Full Text] [Related]
13. Development, formulation, and cellular mechanism of a lipophilic copper chelator for the treatment of Wilson's disease.
Gauthier L; Charbonnier P; Chevallet M; Delangle P; Texier I; Gateau C; Deniaud A
Int J Pharm; 2021 Nov; 609():121193. PubMed ID: 34673167
[TBL] [Abstract][Full Text] [Related]
14. Wilson's disease: a new gene and an animal model for an old disease.
Cuthbert JA
J Investig Med; 1995 Aug; 43(4):323-36. PubMed ID: 7552582
[TBL] [Abstract][Full Text] [Related]
15. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.
Merle U; Schaefer M; Ferenci P; Stremmel W
Gut; 2007 Jan; 56(1):115-20. PubMed ID: 16709660
[TBL] [Abstract][Full Text] [Related]
16. Design of intrahepatocyte copper(I) chelators as drug candidates for Wilson's disease.
Gateau C; Delangle P
Ann N Y Acad Sci; 2014 May; 1315():30-6. PubMed ID: 24611802
[TBL] [Abstract][Full Text] [Related]
17. Metallothionein is elevated in liver and duodenum of Atp7b
Zhang CC; Volkmann M; Tuma S; Stremmel W; Merle U
Biometals; 2018 Aug; 31(4):617-625. PubMed ID: 29732486
[TBL] [Abstract][Full Text] [Related]
18. Constructing "smart" chelators by using an activatable prochelator strategy for the treatment of Wilson's disease.
Wang C; Wang R; Zhao L; Wang S; Liu Y; Zhao J; Dong Y; Liu L; Wei P; Wu ZY; Yi T
Redox Biol; 2024 Apr; 70():103076. PubMed ID: 38340635
[TBL] [Abstract][Full Text] [Related]
19. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
20. Chelation therapy in Wilson's disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators.
Delangle P; Mintz E
Dalton Trans; 2012 Jun; 41(21):6359-70. PubMed ID: 22327203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
